Utilidad de las dosis bajas de una globulina anti-timocito preparada en México en el tratamiento de la anemia aplástica grave

Delgado Lamas, José Luis; López Karpovitch, Xavier; Marín López, Antonio; Presno Bernal, Miguel; Romero García, Fernando; Ruiz Argüelles, Alejandro; Ruiz Argüelles, Guillermo José; Ruiz Gonzales, Daniel S; Taboada, Catalina; Vásques Villegas, Vicente; Zarzosa, Maria Elena.
Rev. Hosp. Clin. Fac. Med. Univ. Säo Paulo ; 42(6): 298-304, nov.-dez. 1987. tab
Artículo en Español | LILACS | ID: lil-52789

Documentos relacionados

  1. Efficacy of Rabbit Antithymocyte Globulin as a First-line Therapy in Children With Aplastic Anemia.
  2. Clinical impact and characteristics of erythroid dysplasia in adult aplastic anaemia: Results from a multicentre registry.
  3. Aplastic anemia in children: How good is immunosuppressive therapy?
  4. [Clinical characteristics of clonal evolution after immunosuppressive therapy in children with severe/very severe aplastic anemia].
  5. Relationship between plasma rabbit anti-thymocyte globulin concentration and immunosuppressive therapy response in patients with severe aplastic anemia.
  6. Interferon-gamma and perforin-positive T cells in acquired aplastic anemia: implication in therapeutic response.
  7. Rabbit antithymocyte globulin dose does not affect response or survival as first-line therapy for acquired aplastic anemia: a multicenter retrospective study.
  8. Horse versus rabbit antithymocyte globulin in immunosuppressive therapy of treatment-naïve aplastic anemia: a systematic review and meta-analysis.
  9. Prospective randomized trial comparing two doses of rabbit anti-thymocyte globulin in patients with severe aplastic anaemia.
  10. Influence of Iron Overload on Immunosuppressive Therapy in Children with Severe Aplastic Anemia.